Abstract
AbstractDisease progression prediction and therapeutic drug target discovery for Coronavirus disease 2019 (COVID-19) are particularly important, as there is still no effective strategy for severe COVID-19 patient treatment. Herein, we performed multi-platform omics analysis of serial plasma and urine samples collected from patients during the course of COVID-19. Integrative analyses of these omics data revealed several potential therapeutic targets, such as ANXA1 and CLEC3B. Molecular changes in plasma indicated dysregulation of macrophage and suppression of T cell functions in severe patients compared to those in non-severe patients. Further, we chose 25 important molecular signatures as potential biomarkers for the prediction of disease severity. The prediction power was validated using corresponding urine samples and plasma samples from new COVID-19 patient cohort, with AUC reached to 0.904 and 0.988, respectively. In conclusion, our omics data proposed not only potential therapeutic targets, but also biomarkers for understanding the pathogenesis of severe COVID-19.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. W.H.O. Coronavirus disease (COVID-19) dashboard. https://covid19.who.int/ (2020).
2. Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 323, 2052–2059 (2020).
3. Livingston, E. & Bucher, K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 323, 1335 (2020).
4. Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 1239–1242 (2020).
5. Chi, Y. et al. Serum cytokine and chemokine profile in relation to the severity of Coronavirus disease 2019 (COVID-19) in China. J. Infect. Dis. 222, 746–754 (2020).
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献